NCT03400098Approved For Marketing不适用
Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).
详细描述
The Program is intended to provided expanded access to Inotersen for eligible patients with hATTR who have limited or no available treatment options.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female at least 18 years of age with a diagnosis of hATTR
- •Symptoms consistent with polyneuropathy
- •Meet Polyneuropathy Disability (PND) Stage I-III requirements
排除标准
- •Known Primary Amyloidosis, Leptomeningeal Amyloidosis or Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
- •Have inadequate cardiac function
- •Have low platelet counts
- •Have inadequate renal function
研究者
相似试验
No Longer Available
不适用
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)Familial ChylomicronemiaNCT03544060Akcea Therapeutics
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
Available
不适用
IFx-Hu2.0 Expanded Access ProgramCutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaNCT04853602TuHURA Biosciences, Inc.
Available
不适用
A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspUveal MelanomaNCT04960891Immunocore Ltd
Temporarily Not Available
不适用
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Castration-Resistant Prostatic CancerNCT06033001Lantheus Medical Imaging